Identification and fermentation optimization of a myxobacterium producing anti-MRSA bioactive products

CHU Fuxin; LI Anzhang; XIE Xiaolin; JIANG Hongxia; ZHU Honghui

doi:10.7671/j.issn.1001-411X.2016.02.004

Journal of South China Agricultural University > 2016 > 37(2): 20-29. > DOI: 10.7671/j.issn.1001-411X.2016.02.004

CHU Fuxin, LI Anzhang, XIE Xiaolin, JIANG Hongxia, ZHU Honghui. Identification and fermentation optimization of a myxobacterium producing anti-MRSA bioactive products[J]. Journal of South China Agricultural University, 2016, 37(2): 20-29. DOI: 10.7671/j.issn.1001-411X.2016.02.004

Citation:

PDF (3164 KB)

Identification and fermentation optimization of a myxobacterium producing anti-MRSA bioactive products

1.
College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China
2.
Guangdong Institute of Microbiology/ State Key Laboratory of Applied Microbiology Southern China/Guangdong Provincial Key Laboratory of Microbial Culture Collection and Application/ Guangdong Open Laboratory of Applied Microbiology, Guangzhou 510070, China

More Information

Received Date: April 20, 2015
Available Online: May 17, 2023

Graphical Abstract

Abstract

Abstract

Objective
In this report, strain GIM1.813 was investigated, prepared for future isolation and identification of anti-methicillin-resistant Staphylococcus aureus (MRSA) bioactive products.
Method
According to colonial morphology, scanning electron microscopy, physiological and biochemical characteristics, and phylogenetic analysis based on 16S rRNA genes, GIM1.813 was identified and classified. The effects of seven mediums on the active compounds producted by strain GIM1.813 were compared. The chosen medium and fermentation conditions were optimized by orthogonal experiments.
Result
The optimal pH and temperature for strain GIM1.813 were 7.0 and 30.0 ℃, respectively, and the strain could tolerate up to 10 g·L^-1 NaCl. The data of physical-chemical characteristics, chromosomal DNA G+C concents and quinines of this strain were also presented. Strain GIM1.813 grew well in all seven tested mediums, while it produced metabolites with the maximum antibacterial activity in IVY/2 medium. After fermentation optimization, the anti-MRSA activity of fermentation broth increased by 49.12% and the strain GIM1.813 grew better.
Conclusion
Strain GIM1.813 was classified as Corallococcus exiguous. Its ability of producing anti-MRSA bioactive components was improved significantly by fermentation optimization. Meanwhile, Mg²⁺ and starch were found to significantly improve the ability of myxobacteria to produce bioactive components.
- myxobacterium,
- natural product,
- MRSA,
- strain identification,
- orthogonal experiment,
- fermentation optimization

FullText(HTML)

References (36)

References

[1]	KLEVENS R M, MORRISON M A, NADLE J, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States[J]. JAMA, 2007, 298(15): 1763-1771. doi: 10.1001/jama.298.15.1763
[2]	FRAZEE B W, LYNN J, CHARLEBOIS E D, et al. High prevalence of methicillin-resistant Staphylococcus aureus in emergency department skin and soft tissue infections[J]. Ann Emerg Med, 2005, 45(3): 311-320. doi: 10.1016/j.annemergmed.2004.10.011
[3]	VANDERHAEGHEN W, HERMANS K, HAESEBROUCK F, et al. Methicillin-resistant Staphylococcus aureus (MRSA) in food production animals[J]. Epidemiol Infect, 2010, 138(5): 606-625. doi: 10.1017/S0950268809991567
[4]	FUSCO N M, TOUSSAINT K A, PRESCOTT W A. Antibiotic management of methicillin-resistant Staphylococcus aureus-associated acute pulmonary exacerbations in cystic fibrosis[J]. Ann Pharmacother, 2015, 49(4):458-468. doi: 10.1177/1060028014567526
[5]	GEORGE S, ROBERT C M. Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureusstrains[J].Clin Infect Dis, 2008, 46(5): S360-S367.
[6]	NEWMAN D J, CRAGG G M. Natural products as sources of new drugs over the 30 years from 1981 to 2010[J]. J Nat Prod, 2012, 75(3): 311-335. doi: 10.1021/np200906s
[7]	SINGH S B, BARRETT J F. Empirical antibacterial drug discovery:foundation in natural products[J]. Biochem Pharmacol, 2006, 71(7): 1006-1015. doi: 10.1016/j.bcp.2005.12.016
[8]	张哲峰.多重耐药菌的监控与新抗生素研发[J].中国药学杂志, 2014, 49(14):1268-1273.
[9]	BERDY J. Bioactive microbial metabolites[J]. J Antibiot, 2005, 58(1): 1-26. doi: 10.1038/ja.2005.1
[10]	刘少伟, 韩晓艳, 刘佳萌, 等. 塔克拉玛干沙漠来源抗MRSA新抗生素—和田霉素A-D[C]//中国药学会抗生素专业委员会. 第十二届全国抗生素学术会议论文集. 成都. 出版地不详: 出版者不详, 2013: 76-86.
[11]	武英, 王辂.开发微生物来源天然产物的新技术[J].国外医药(抗生素分册), 2010, 31(1): 1-6. http://d.old.wanfangdata.com.cn/Periodical/gwyykssfc201001001
[12]	WEISSMAN KJ, MVLLER R. Myxobacterial secondary metabolites: Bioactivities and modes-of-action[J]. Nat Prod Rep, 2010, 27(9): 1276-1295. doi: 10.1039/c001260m
[13]	李艳利, 张荫雷, 刘迎, 等.一株新粘细菌生物学性质的研究[J].微生物学通报, 2008, 35(23): 1888-1891. http://d.old.wanfangdata.com.cn/Periodical/wswxtb200812007
[14]	王海英, 张利平.粘细菌:一类重要的微生物资源[J].微生物学通报, 2003, 30(2): 115-116. doi: 10.3969/j.issn.0253-2654.2003.02.029
[15]	SCH BERLE T F, LOHR F, SCHMITZ A, et al. Antibiotics from myxobacteria[J]. Nat Prod Rep, 2014, 31: 953-972. doi: 10.1039/c4np00011k
[16]	GERTH K, PRADELLA S, PERLOVA O, et al. Myxobacteria: Proficient producers of novel natural products with various biological activities:past and future biotechnological aspects with the focus on the genus Sorangium[J]. J Biotechnol, 2003, 106(2): 233-253. http://d.old.wanfangdata.com.cn/Periodical/wswxb200006015
[17]	GASPARI F, PAITAN Y, MAININI M, et al. Myxobacteria isolated in Israel as potential source of new anti-infectives[J]. J Appl Microbiol, 2005, 98(2): 429-439. doi: 10.1111/jam.2005.98.issue-2
[18]	WANG D, YUAN J, TAO W. Identification of a novel antibiotic from myxobacterium Stigmatella eracta WXNXJ-B and evaluation of its antitumor effects in-vitro[J].Iran J Pharmaceut Res, 2014, 13(1): 171.
[19]	GUO W J, TAO W Y, XU Z H, et al. Directed-screening of myxobacteria producing high bioactive antitumor metabolites[J]. Nat Pro Res Dev, 2007, 19(6):1032-1036. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=trcwyjykf200706028
[20]	施晓琼, 许强芝, 刘小宇, 等.六种粘细菌095b06次生代谢产物的分离、鉴定及初步生物学活性研究[J].第二军医大学学报, 2007, 28(3): 266-271. doi: 10.3321/j.issn:0258-879X.2007.03.008
[21]	GARRITY G M. Bergey's manual of systematic bacteriology[M]. Berlin: Springer, 2006:1079-1082.
[22]	BRUNEL B, GIVAUDAN A, LANOIS A, et al. Fast and accurate identification of Xenorhabdus and Photorhabdus species by restriction analysis of PCR-amplified 16S rRNA genes[J]. Appl Environ Microb, 1997, 63(2): 574-580. http://d.old.wanfangdata.com.cn/OAPaper/oai_pubmedcentral.nih.gov_168349
[23]	东秀珠, 蔡妙英.常见细菌系统鉴定手册[M].北京:科学出版社, 2001: 370-398.
[24]	MESBAH M, PREMACHANDRAN U, WHITMAN W B. Precise measurement of the G+C content of deoxyribonucleic acid by high-performance liquid chromatography[J]. Int J Syst Bacteriol, 1989, 39(2): 159-167. doi: 10.1099/00207713-39-2-159
[25]	COLLINS M, PIROUZ T, GOODFELLOW M, et al. Distribution of menaquinones in actinomycetes and corynebacteria[J]. J Gen Microbiol, 1977, 100(2): 221-230. doi: 10.1099/00221287-100-2-221
[26]	FYHRQUIST P, MWASUMBI L, HAGGSTRÖM C A, et al. Ethnobotanical and antimicrobial investigation on some species of Terminalia and Combretum(Combretaceae) growing in Tanzania[J]. J Ethnopharmacol, 2002, 79(2): 169-177. doi: 10.1016/S0378-8741(01)00375-0
[27]	原红娟. 热带亚热带原始森林粘细菌的多样性研究[D]. 广州: 华南农业大学, 2014.
[28]	REICHENBACH H. Myxobacteria, producers of novel bioactive substances[J]. J Ind Microbiol Biotechnol, 2001, 27(3): 149-156. doi: 10.1038/sj.jim.7000025
[29]	李越中, 李健, 周璐, 等.我国粘细菌(Myxobacteria)资源的分离与鉴定[J].微生物学报, 2000, 40(6): 652-656. doi: 10.3321/j.issn:0001-6209.2000.06.015
[30]	SHIMKETS L J, DWORKIN M, REICHENBACH H. The prokaryotes[M]. Berlin: Springer, 2006: 31-115.
[31]	BRETSCHER A P, KAISER D. Nutrition of Myxococcus xanthus, a fruiting myxobacterium[J]. J Bacteriol, 1978, 133(2): 763-768. http://d.old.wanfangdata.com.cn/OAPaper/oai_pubmedcentral.nih.gov_222085
[32]	王大红. 粘细菌Stigmatella WXNXJ-B产生新型抗肿瘤抗生素的研究[D]. 无锡: 江南大学, 2010.
[33]	GERTH K, IRSCHIK H, JANSEN R, et al. Myxobacteria-the word is spreading [J]. [EB/OL]. [2015-04-21]. http://www.naturstoff-forschung.info/nafo_media/13+myxobacteria.pdf.
[34]	胡玮, 李越中, 李曦, 等.珊瑚状珊瑚球菌Cc9736抗肿瘤活性组分的分离纯化[J].中国抗生素杂志, 2000, 25(4): 309-311. doi: 10.3969/j.issn.1001-8689.2000.04.021
[35]	鞠培殿. Corallococcus coralloides 085B04次级代谢产物的分离与结构表征[D]. 济南: 山东轻工业学院, 2010.
[36]	李健, 郭新征, 李越中, 等.具有抑瘤活性的粘细菌珊瑚状珊瑚球菌Cc9736发酵产物的初步研究[J].中国抗生素杂志, 1999, 24(4): 308-309. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=QK199900874821